06/13/2023
We are excited to share some recent highlights from Genetic Engineering & Biotechnology News (GEN) about our work at Siolta Therapeutics. We're pioneering the development of live bacterial products (LBPs) aimed at restoring health by rebalancing the microbiome.
At Siolta, we believe understanding and leveraging the microbiome's systemic impact can revolutionize how we approach a wide range of diseases. We're not just treating disease but preventing it - a true game changer in healthcare.
Our lead product, STMC-103H, is currently under a Phase II trial (the ADORED Study) for preventing atopic dermatitis in newborns. It aims to reprogram the microbiome of children who have a microbial signature linked to disease-driving metabolic and immunological functions. For more information, please visit www.adoredstudy.com.
We also have preclinical programs focused on recurrent bacterial vaginosis, a condition that affects women's ability to have healthy pregnancies, and necrotizing enterocolitis, a rare pediatric indication affecting preterm babies.
Read the full article here: https://lnkd.in/d9vEBK6k
Thank you for your support as we continue to push the boundaries of microbiome science!
Knowing the differences between peaceable and fractious microbiomes helps biotech companies create diagnostic tools and therapeutic interventions.
